Caregen Co.Ltd (214370) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Caregen Co.Ltd (214370) has a cash flow conversion efficiency ratio of 0.019x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩4.16 Billion ≈ $2.82 Million USD) by net assets (₩216.88 Billion ≈ $146.97 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 214370 net asset quality index to measure how much of total assets are equity-financed.
Caregen Co.Ltd - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Caregen Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Caregen Co.Ltd earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Caregen Co.Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Caregen Co.Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Weave Communications Inc
NYSE:WEAV
|
0.077x |
|
Kunshan Asia Aroma Corp. Ltd.
SHE:301220
|
0.002x |
|
Haypp Grp Ab
ST:HAYPP
|
0.035x |
|
Anhui Jinchun Nonwoven Co Ltd
SHE:300877
|
-0.067x |
|
Nam Long Investment Corp
VN:NLG
|
0.009x |
|
Delek Automotive Systems Ltd
TA:DLEA
|
0.164x |
|
Zhejiang Red Dragonfly Footwear Co Ltd
SHG:603116
|
-0.006x |
|
Zota Health Care LImited
NSE:ZOTA
|
-0.157x |
Annual Cash Flow Conversion Efficiency for Caregen Co.Ltd (2015–2024)
The table below shows the annual cash flow conversion efficiency of Caregen Co.Ltd from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see Caregen Co.Ltd (214370) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩222.98 Billion ≈ $151.11 Million |
₩13.49 Billion ≈ $9.14 Million |
0.060x | -51.93% |
| 2023-12-31 | ₩227.30 Billion ≈ $154.04 Million |
₩28.60 Billion ≈ $19.38 Million |
0.126x | +198.20% |
| 2022-12-31 | ₩215.98 Billion ≈ $146.37 Million |
₩-27.68 Billion ≈ $-18.76 Million |
-0.128x | -151.82% |
| 2021-12-31 | ₩209.72 Billion ≈ $142.12 Million |
₩51.86 Billion ≈ $35.14 Million |
0.247x | +64.84% |
| 2020-12-31 | ₩205.16 Billion ≈ $139.03 Million |
₩30.78 Billion ≈ $20.86 Million |
0.150x | -53.27% |
| 2019-12-31 | ₩217.01 Billion ≈ $147.06 Million |
₩69.66 Billion ≈ $47.21 Million |
0.321x | +1063.53% |
| 2018-12-31 | ₩204.75 Billion ≈ $138.76 Million |
₩-6.82 Billion ≈ $-4.62 Million |
-0.033x | -116.13% |
| 2017-12-31 | ₩231.83 Billion ≈ $157.11 Million |
₩47.88 Billion ≈ $32.45 Million |
0.207x | +403.39% |
| 2016-12-31 | ₩234.11 Billion ≈ $158.65 Million |
₩-15.94 Billion ≈ $-10.80 Million |
-0.068x | -1180.76% |
| 2015-12-31 | ₩248.87 Billion ≈ $168.66 Million |
₩1.57 Billion ≈ $1.06 Million |
0.006x | -- |
About Caregen Co.Ltd
Caregen Co., Ltd. engages in the research, development, and commercialization of biomimetic peptides and growth factors worldwide. The company offers cosmeceutical products and food supplements under the Dermaheal, Renokin, Deglusterol, PURILUX, Pelo Baum, Pim-Pim-Paul, Neovert, and PTx brands. It also provides medical devices under the REVOFIL, DR.CYJ, PROSTROLANE, PROSTROLANE B-Series, and CG S… Read more